| Identification | Back Directory | [Name]
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α | [CAS]
294856-01-2 | [Synonyms]
GGAGMUSEFHEEBF-XPRPYWGDSA-N
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α
5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-[3-(trifluoromethyl)phenyl]pentyl]cyclopentyl]-, (5Z)- | [Molecular Formula]
C24H33F3O5 | [MDL Number]
MFCD05863955 | [MOL File]
294856-01-2.mol | [Molecular Weight]
458.51 |
| Hazard Information | Back Directory | [Description]
A number of 17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma. Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects. 17-trifluoromethylphenyl-13,14-dihydro trinor PGF2α bears an aromatic ring which is reminiscent of the trifluoromethyl-phenoxy ring of travoprost ((+)-fluprostenol isopropyl ester). As an ocular hypotensive agent, it would be expected that 17-trifluoromethylphenyl-13,14-dihydro trinor PGF2α would act very much like the free acid of latanoprost. |
|
|